AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
Azenta, Inc. (Nasdaq: AZTA) has announced a significant leadership change. John P. Marotta will join as President and CEO on September 9, 2024, succeeding retiring Dr. Stephen Schwartz. Marotta brings two decades of experience in life sciences, medical devices, and diagnostics. He joins from Patient Square Capital and previously served as CEO of PHC Holdings The appointment follows a rigorous search process led by the Board. Frank E. Casal, Chairman of Azenta's Board, expressed confidence in Marotta's ability to lead the company's next growth phase. Dr. Schwartz, who led Azenta for 14 years, will remain as an advisor to ensure a smooth transition.
Azenta, Inc. (Nasdaq: AZTA) ha annunciato un importante cambio alla guida. John P. Marotta assumerà il ruolo di Presidente e CEO il 9 settembre 2024, succedendo al dimissionario Dr. Stephen Schwartz. Marotta porta con sé due decenni di esperienza nelle scienze della vita, nei dispositivi medici e nella diagnostica. Proviene da Patient Square Capital e in precedenza ha ricoperto il ruolo di CEO di PHC Holdings. La nomina segue un rigoroso processo di selezione condotto dal Consiglio. Frank E. Casal, Presidente del Consiglio di Azenta, ha espresso fiducia nella capacità di Marotta di guidare la prossima fase di crescita dell'azienda. Il Dr. Schwartz, che ha guidato Azenta per 14 anni, rimarrà come consulente per garantire una transizione fluida.
Azenta, Inc. (Nasdaq: AZTA) ha anunciado un cambio significativo en su liderazgo. John P. Marotta se unirá como Presidente y CEO el 9 de septiembre de 2024, sucediendo al que se retira, Dr. Stephen Schwartz. Marotta aporta dos décadas de experiencia en ciencias de la vida, dispositivos médicos y diagnósticos. Se une desde Patient Square Capital y anteriormente fue CEO de PHC Holdings. La designación sigue un riguroso proceso de búsqueda liderado por la Junta. Frank E. Casal, Presidente de la Junta de Azenta, expresó confianza en la capacidad de Marotta para liderar la próxima fase de crecimiento de la empresa. El Dr. Schwartz, que dirigió Azenta durante 14 años, permanecerá como asesor para asegurar una transición suave.
Azenta, Inc. (Nasdaq: AZTA)는 중요한 경영진 변화를 발표했습니다. John P. Marotta가 2024년 9월 9일에 사임하는 Dr. Stephen Schwartz를 이어받아 사장 겸 CEO로 합류합니다. Marotta는 생명과학, 의료기기 및 진단 분야에서 20년의 경험을 가지고 있습니다. 그는 Patient Square Capital에서 합류하며, 이전에는 PHC Holdings의 CEO로 재직했습니다. 이번 임명은 이사회가 주도한 엄격한 검색 과정을 거쳤습니다. Frank E. Casal, Azenta 이사회의 의장은 Marotta가 회사의 다음 성장 단계 를 이끌 수 있는 능력에 대해 확신을 표명했습니다. 14년 동안 Azenta를 이끌었던 Dr. Schwartz는 원활한 전환을 위해 고문으로 남을 것입니다.
Azenta, Inc. (Nasdaq: AZTA) a annoncé un changement de direction significatif. John P. Marotta rejoindra l'entreprise en tant que Président et PDG le 9 septembre 2024, succédant au Dr. Stephen Schwartz qui part à la retraite. Marotta apporte deux décennies d'expérience dans les sciences de la vie, les dispositifs médicaux et le diagnostic. Il rejoint Azenta après avoir travaillé chez Patient Square Capital et a précédemment été CEO de PHC Holdings. Cette nomination fait suite à un processus de recherche rigoureux mené par le Conseil d'Administration. Frank E. Casal, Président du Conseil d'Azenta, a exprimé sa confiance dans la capacité de Marotta à diriger la prochaine phase de croissance de l'entreprise. Le Dr. Schwartz, qui a dirigé Azenta pendant 14 ans, restera conseiller pour garantir une transition en douceur.
Azenta, Inc. (Nasdaq: AZTA) hat eine bedeutende Veränderung in der Führung angekündigt. John P. Marotta wird am 9. September 2024 als Präsident und CEO einsteigen und wird den zurücktretenden Dr. Stephen Schwartz ersetzen. Marotta bringt zwei Jahrzehnte Erfahrung in den Bereichen Lebenswissenschaften, Medizinprodukte und Diagnostik mit. Er wechselt von Patient Square Capital und war zuvor CEO von PHC Holdings. Die Ernennung folgt einem strengen Auswahlprozess, der vom Vorstand geleitet wurde. Frank E. Casal, Vorsitzender des Azenta-Vorstands, äußerte Vertrauen in Marottas Fähigkeit, die nächste Wachstumsphase des Unternehmens zu führen. Dr. Schwartz, der Azenta 14 Jahre lang geleitet hat, wird als Berater bleiben, um einen reibungslosen Übergang zu gewährleisten.
- Appointment of John P. Marotta as new CEO, bringing extensive experience in life sciences and medical devices
- Smooth transition planned with Dr. Schwartz remaining as an advisor
- New leadership potentially bringing fresh perspectives and strategies for growth
- Departure of long-standing CEO Dr. Stephen Schwartz after 14 years
- Potential short-term uncertainty during leadership transition
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure
Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues and leading its IPO from owners KKR & Co. He also held a variety of senior executive roles in leading life sciences companies, including at Danaher Corporation, Envista Holdings Corporation, and Cardinal Health, Inc., where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.
Frank E. Casal, Chairman of the Azenta Board said, "Following a rigorous search process, aided by a leading executive search firm, the Board and I are thrilled to welcome John as our next President and CEO. We are confident he is the ideal person to lead Azenta into our next chapter. John brings extensive experience leading complex high-growth life sciences businesses around the globe. We look forward to working with him to amplify Azenta's momentum and deliver sustainable value for shareholders."
Mr. Marotta said, "I am excited to join Azenta and get to know its talented teams worldwide. I have been impressed by Azenta's evolution and am confident that, together, we will expand on its strong foundation to further enhance its offerings while driving growth and profitability. I look forward to hitting the ground running and executing on our tremendous opportunities ahead."
Mr. Casal continued, "The Board and I extend our deepest gratitude to Steve for his leadership over the last 14 years. Steve joined as President of Brooks Automation in April 2010 and was appointed CEO in August 2010. He led the creation of Azenta as a business division of Brooks into the standalone, pure-play life-sciences leader that it is today, and oversaw the sale of the Semiconductor Solutions Group. Steve leaves a profound impression on all stakeholders, having led our team to create significant value for shareholders during his tenure and enable customers to realize impactful breakthroughs. We thank Steve and wish him all the best."
Dr. Schwartz added, "It has been a privilege to be a part of this amazing Azenta team on a journey to become an established life-sciences company that we believe uniquely enables customers around the globe in their pursuit of scientific progress. I am confident in Azenta's future success as it moves into this next chapter and I look forward to working with John through the transition."
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
Azenta is headquartered in Burlington,
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about the transition to John P. Marotta as Azenta's President and CEO and ability to deliver shareholder value. Factors that could cause results to differ from our expectations include the following: our ability to ensure a smooth CEO transition; our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.
AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
AZENTA MEDIA CONTACT:
Emily Claffey
FGS Global
Azenta@FGSGlobal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-appointment-of-john-p-marotta-as-ceo-302237689.html
SOURCE Azenta
FAQ
When will John P. Marotta start as CEO of Azenta (AZTA)?
Who is John P. Marotta replacing as CEO of Azenta (AZTA)?
What is John P. Marotta's background before joining Azenta (AZTA)?
How long did Dr. Stephen Schwartz serve as CEO of Azenta (AZTA)?
